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The Search for Meaning in Diffusion-Weighted Brain Lesions*William A. Gray, MD“The process of scientiﬁc discovery is, in effect,
a continual ﬂight from wonder.”
—Albert Einstein (1)C arotid endarterectomy (CEA) and carotidartery stenting (CAS) can be considered forpatients with carotid artery bifurcation dis-
ease on optimized medical therapy who have been
determined to require additional treatment. In CREST
(Carotid Revascularization Endarterectomy versus
Stenting Trial), the largest, most rigorous trial com-
paring these 2 strategies in both symptomatic and
asymptomatic subjects, there were no differences in
the primary endpoint of death, stroke, and myocar-
dial infarction at 30 days plus ipsilateral stroke to 4
years (2). Subsequently, efforts have been made to
analyze the trial’s data to gain a better understanding
of the comparative early safety of these therapies
(3,4); the long-term data on death, stroke prevention,
and need for repeat revascularization are indistin-
guishable. However, efforts at stratiﬁcation or con-
structing predictors of the 30-day outcomes of CEA
and CAS according to clinical or procedural character-
istics are confounded by 1 simple, unassailable fact:
the number of outcome events in carotid intervention
is too small to achieve statistical signiﬁcance in most
cases. For example, in the intention-to-treat analysis
of the 2,502 randomized CREST subjects, a total of 79
periprocedural stroke events occurred, and in the
only group in which there were differences between
the therapies (the minor ipsilateral events), there*Editorials published in the Journal of the American College of Cardiology
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disclose.were only 54 events, and these were split even
further between CEA and CAS.
The low event rates in CEA and CAS are reassuring
for both patients and their treating physicians. How-
ever, these low rates have frustrated investigators
and have led to efforts to identify surrogate markers
of outcomes that speak to the mechanistic aspects of
the procedures (or the associated complications),
even if there is no well-established clinical correlate.
An example of such a surrogate is transcranial
Doppler (TCD), which can be useful in determining
intraprocedural cerebral hemodynamic status and
can detect intraprocedural embolic signals in the
intracranial circulation with remarkable detail and
accuracy. However, TCD is plagued by signiﬁcant
problems regarding emboli detection: it struggles to
distinguish solid from gaseous emboli from a variety
of presumably benign sources such as contrast and
sheath withdrawal on ﬁlter (5). Thus, although TCD
can be helpful in identifying certain procedural or
operative steps that may be more likely to produce
emboli, it lacks the capability to distinguish the
gravity, and thus impact, of the ﬁndings.
Magnetic resonance diffusion-weighted imaging
(MR-DWI) has also been proposed as a surrogate.
Practically every diagnostic or interventional proce-
dure that passes through the aortic arch has been
associated with new MR-DWI lesions, as has cardiac
surgery on- and off-pump (6,7). Lesions seen on
MR-DWI reﬂect the intracellular movement of water
and the resultant cytotoxic edema, ﬁndings that
are believed to be indicative of early pathological
changes as a result of acute ischemia. MR-DWI has the
advantage of being reliably quantiﬁable and repre-
sentative of these presumably meaningful cellular
changes as the result of a procedure or operation
and frequent enough to be analyzable as an end-
point; the clinical import of these lesions (which are
overwhelmingly asymptomatic), however, has been
J A C C V O L . 6 5 , N O . 6 , 2 0 1 5 Gray
F E B R U A R Y 1 7 , 2 0 1 5 : 5 3 0 – 2 Diffusion-Weighted Brain Lesions
531unclear. MR-DWI abnormalities occurring “in the
wild,” without an associated procedure, have been
associated with an increased risk of cognitive
dysfunction and dementia (8). This has led some to
advance the concept that iatrogenically produced le-
sions carry a similar risk of long-term decline. This
speculation, however, fails to acknowledge both the
likely different pathological basis of each lesion set
(the “wild” version is likely related to intrinsic cere-
bral microvascular disease rather than embolic in
nature) as well as the presumed lack of chronicity of
the procedural embolic type. Despite several at-
tempts, no clear clinical association has been found
between cognitive decline and MR-DWI lesions after
vascular operation or intervention (9–11). However,
there has been a recurrent ﬁnding of a greater number
of asymptomatic lesions associated with ﬁlter-
protected CAS compared with proximally protected
CAS or CEA. In addition, the observation that there is
a generally small but numerically greater incidence of
minor strokes after CAS compared with CEA raises the
hope that if the excess of new MR-DWI lesions could
be reduced, then the minor stroke rate might also be
expected to drop.SEE PAGE 521The study by Gensicke et al. (12) in this issue of
the Journal seeks to more deﬁnitively correlate the
occurrence of post-procedural MR-DWI lesions with a
clinical outcome. The investigators conducted an
analysis (presumably exploratory because it is not
declared as prespeciﬁed) concerning the incidence of
transient ischemic attack (TIA) and stroke inw4 years
of follow-up after CEA or CAS in a small (231 patients)
substudy of ICSS (International Carotid Stenting
Study). The main 1,713-patient study found no dif-
ference in the primary endpoint of disabling or fatal
stroke at 3 years in symptomatic patients (13). This
cohort of patients from the ICSS magnetic resonance
imaging substudy has been the subject of several
other analyses and publications, including an analysis
that failed to ﬁnd any cognitive differences between
CEA and CAS in ICSS despite the higher incidence of
MR-DWI lesions in the CAS group (14,15). Thus,
characterizing this cohort is important to fully un-
derstand the science that it has generated. Unfortu-
nately, the ICSS study requirements for CAS operator
experience were sparse by any contemporary stan-
dard, with a requirement of only 10 CAS procedures.
Moreover, only w40% of the CAS patients in this
substudy received an embolic protection device as
part of their CAS procedure. These issues signiﬁcantly
mitigate the impact of the substudy’s ﬁndingsbecause it does not represent expertly performed CAS
using standard equipment.
Nevertheless, the authors (12) observed that pa-
tients with new MR-DWI lesions post-procedure were
more numerous in the CAS group; that same group
also had more total TIA and stroke events in the
ensuing follow-up period, which was not true for the
CEA group with new lesions. The baseline character-
istics between patients with versus without peri-
procedural DWI lesions were different and potentially
confounding: the patients were older, had more
baseline age-related white matter changes, and ten-
ded to be more hypertensive (a known independent
risk factor for stroke). The outcomes were ultimately
adjusted, but the primary results were unaffected.
In addition, because the difference in event rates
between the patients with versus without periproce-
dural DWI lesions occurred in the ﬁrst 6 months, the
authors speculated that the lack of a dual antiplatelet
therapy (DAPT) may have been responsible for this
ﬁnding.
Although it is tempting to accept these conclusions
(12) in the quest for consequences in post-procedural
MR-DWI lesions, the results warrant closer examina-
tion. First, TIA is not a typical endpoint in the long-
term follow-up of CEA and CAS, and its use is
generally incorporated to increase outcome events
that might drive differences; the fact that the deter-
mination of TIA is largely a clinical one and not
objectiﬁed in imaging also makes it somewhat prob-
lematic. In addition, when the analysis was limited to
only TIA or stroke in the territory served by the index
carotid, or any stroke but excluding TIA, there was no
association between the ﬁnding of new lesions and
subsequent neurological events. Second, atrial ﬁbril-
lation was not reported or adjusted for and could
clearly have confounded the analysis. Third, the
sidedness of the MR-DWI lesions was not speciﬁed
and therefore could not be clearly correlated with
the intervention, even accepting that contralateral
lesions may be seen from aortic arch manipulations.
As a result of these issues, the mechanistic cause for
the primary endpoint ﬁnding is called into question,
as are any derivative suppositions regarding the
duration of DAPT. Moreover, the study that was
quoted as additional support for aggressive DAPT was
small (n ¼ 156) and also relied almost exclusively on
differences in MR-DWI ﬁndings and the addition of
TIA in their endpoint (16). Given the lack of differ-
entiation between hard endpoints between the 2
therapies in the present study, along with the small
but real increase in bleeding, extended DAPT does not
seem justiﬁed or advisable. Unfortunately, although
carefully conducted by a group of high-quality
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532investigators, the study by Gensicke et al. (12) fails to
shed light on the clinical relevance of MR-DWI ab-
normalities associated with carotid procedures or
operations.
On this subject, ﬂights from wonder must therefore
continue.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
William A. Gray, Center for Interventional Vascular
Therapy, Columbia University Medical Center, 161
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